This study focuses on Secondary Hemophagocytic Lymphohistiocytosis (sHLH), a severe condition where the immune system becomes overactive and damages the body’s own tissues. The study will test a new medication called ELA026, which is given through intravenous infusion. The purpose is to evaluate how well this treatment works in patients who have sHLH that developed as a result of having lymphoma, a type of blood cancer.

The study will monitor patients who receive ELA026 for up to 90 days to assess their response to treatment. The main focus will be on checking if patients survive for at least 56 days after starting treatment. During the study, patients will receive the medication through an intravenous line, and their condition will be closely monitored by healthcare professionals.

Throughout the treatment period, which may last up to 85 days, doctors will track how well patients respond to ELA026 by looking at various signs of improvement in their condition. They will also monitor for any side effects that might occur during the treatment. This is an open-label study, which means both doctors and patients will know which treatment is being given.